Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study - PubMed (original) (raw)

Clinical Trial

. 1994 Jan-Feb;18(1):150-5.

doi: 10.1007/BF00348209.

Affiliations

• PMID: 8197772
• DOI: 10.1007/BF00348209

Clinical Trial

Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study

T Fujimura et al. World J Surg. 1994 Jan-Feb.

Abstract

We performed continuous hyperthermic peritoneal perfusion (CHPP) or continuous normothermic peritoneal perfusion (CNPP) combined with cisplatin (CDDP) 300 mg/kg and mitomycin C (MMC) 30 mg/kg in an attempt to prevent peritoneal recurrence after surgery for gastric cancer. Twenty-two patients were treated with perfusion using about 10 liters of saline heated to 41 degrees to 42 degrees C (CNPP group); 18 patients were treated with saline heated to 37 degrees to 38 degrees C (CNPP group); and 18 patients underwent only gastric surgery without perfusion (control group) in a randomized control study. There were two deaths (9%) due to peritoneal recurrence in the CHPP group, four (22%) in the CNPP group, and four (22%) in the control group. The 1-, 2-, and 3-year survival rates were 95%, 89%, and 68%, in the CHPP group; 81%, 75%, and 51%, in the CNPP group; and 43%, 23%, and 23%, in the control group, respectively. There was a significant difference between the three survival curves by the log-rank test (p < 0.01). This difference showed that CNPP and CHPP are both effective procedures for preventing peritoneal recurrence. The maximum concentrations in the perfusate of total and free CDDP with 300 mg administration were 12.2 and 10.1 micrograms/ml, respectively, at the end of the perfusion, and the maximum concentrations of total and free CDDP in plasma were 2.1 and 1.0 micrograms/ml, respectively. The maximum concentrations of MMC in perfusate and plasma with 30 mg administration were 1.00 and 0.05 micrograms/ml, respectively, which are intraperitoneally cytotoxic but systemically safe concentrations.

PubMed Disclaimer

Similar articles

• Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study.
  Yonemura Y, de Aretxabala X, Fujimura T, Fushida S, Katayama K, Bandou E, Sugiyama K, Kawamura T, Kinoshita K, Endou Y, Sasaki T. Yonemura Y, et al. Hepatogastroenterology. 2001 Nov-Dec;48(42):1776-82. Hepatogastroenterology. 2001. PMID: 11813623 Clinical Trial.
• [Continuous hyperthermic peritoneal perfusion with cisplatin and mitomycin C for peritoneal dissemination in gastric cancer].
  Fujimura T, Yonemura Y, Urade M, Sugiyama K, Hasegawa H, Hashimoto T, Miyata R, Matsuda Y, Katayama K, Yamaguchi A, et al. Fujimura T, et al. Nihon Gan Chiryo Gakkai Shi. 1989 Jul 20;24(7):1415-24. Nihon Gan Chiryo Gakkai Shi. 1989. PMID: 2509604 Japanese.
• Does hyperthermia induce peritoneal damage in continuous hyperthermic peritoneal perfusion?
  Shido A, Ohmura S, Yamamoto K, Kobayashi T, Fujimura T, Yonemura Y. Shido A, et al. World J Surg. 2000 May;24(5):507-11. doi: 10.1007/s002689910081. World J Surg. 2000. PMID: 10787067 Clinical Trial.
• [Prophylaxis and treatment of peritoneal metastasis from gastric cancer].
  Kaibara N. Kaibara N. Nihon Geka Gakkai Zasshi. 1996 Apr;97(4):308-11. Nihon Geka Gakkai Zasshi. 1996. PMID: 8692149 Review. Japanese.
• [Chemo-hyperthermic peritoneal perfusion for therapy of advanced gastric cancer with peritoneal dissemination].
  Ikeguchi M, Kaibara N. Ikeguchi M, et al. Nihon Rinsho. 2001 Apr;59 Suppl 4:469-72. Nihon Rinsho. 2001. PMID: 11424427 Review. Japanese. No abstract available.

Cited by

• Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosis.
  Valenzuela B, Nalda-Molina R, Bretcha-Boix P, Escudero-Ortíz V, Duart MJ, Carbonell V, Sureda M, Rebollo JP, Farré J, Brugarolas A, Pérez-Ruixo JJ. Valenzuela B, et al. AAPS J. 2011 Mar;13(1):72-82. doi: 10.1208/s12248-010-9249-2. Epub 2011 Jan 6. AAPS J. 2011. PMID: 21210260 Free PMC article.
• Hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: A multicenter propensity score-matched cohort study.
  Lei Z, Wang J, Li Z, Li B, Luo J, Wang X, Wang J, Ba M, Tang H, He Q, Liao Q, Yang X, Guan T, Liang H, Cui S, On Behalf Of The Chinese Peritoneal Oncology Study Group. Lei Z, et al. Chin J Cancer Res. 2020 Dec 31;32(6):794-803. doi: 10.21147/j.issn.1000-9604.2020.06.12. Chin J Cancer Res. 2020. PMID: 33447001 Free PMC article.
• Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery for gastric carcinoma at high risk of peritoneal carcinomatosis: short and long-term outcomes (GOETH STUDY)-a collaborative randomized controlled trial by ACOI, FONDAZIONE AIOM, SIC, SICE, and SICO.
  Di Giorgio A, Gerardi C, Abatini C, Melotti G, Bonavina L, Torri V, Santullo F, Garattini S, De Luca M, Rulli E, Rulli E, Pacelli F; GOETH Investigators. Di Giorgio A, et al. Trials. 2022 Dec 1;23(1):969. doi: 10.1186/s13063-022-06880-y. Trials. 2022. PMID: 36457115 Free PMC article. Clinical Trial.
• Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis.
  Magge D, Zenati M, Mavanur A, Winer J, Ramalingam L, Jones H, Zureikat A, Holtzman M, Lee K, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA. Magge D, et al. Ann Surg Oncol. 2014 May;21(5):1448-55. doi: 10.1245/s10434-013-3327-5. Epub 2013 Nov 7. Ann Surg Oncol. 2014. PMID: 24197761 Free PMC article.
• Efficacy and safety of intraperitoneal chemotherapy in patients with advanced gastric cancer: a cumulative meta-analysis of randomized controlled trials.
  He Z, Zhao TT, Xu HM, Wang ZN, Xu YY, Song YX, Ni ZR, Xu H, Yin SC, Liu XY, Miao ZF. He Z, et al. Oncotarget. 2017 Sep 11;8(46):81125-81136. doi: 10.18632/oncotarget.20818. eCollection 2017 Oct 6. Oncotarget. 2017. PMID: 29113372 Free PMC article.

References

1. 1. Cancer Treat Rep. 1983 Sep;67(9):805-10 - PubMed
2. 1. Br J Radiol. 1979 Aug;52(620):657-62 - PubMed
3. 1. Nihon Gan Chiryo Gakkai Shi. 1989 Jul 20;24(7):1415-24 - PubMed
4. 1. Acta Cytol. 1978 Jul-Aug;22(4):225-9 - PubMed
5. 1. Cancer Treat Rep. 1983 Mar;67(3):235-8 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information